Tusamitamab ravtansine
As of the edition of 20 October 2026, Tusamitamab ravtansine is an antibody drug conjugate: stopped in 2026; acts on CEACAM5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Antibody drug conjugate
- Registered trials
- 11, 10 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Tusamitamab ravtansine.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CEACAM5 | Cell adhesion molecule CEACAM5 | P06731 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 7 | 0 | 0 | 7 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2014 to now |
| Innovent Biologics | Lead sponsor of trials | 2023 to now |